南予医学雑誌19巻

43/92

河野、他：PCI施行患者の脂質低下療法南予医誌　Vol.19　No. １　2019－41－３）　 Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, et al. Early statin treatment in patients with acute coronary syndrome: demonstra-tion of the benecial effect on athero-sclerotic lesions by serial volumetric intravascular ultrasound analysis dur-ing half a year after coronary event: the ESTABLISH Study. Circulation 2004;110:1061-1068.４）　 Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.５）　 Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N （表５）イベント再発症例におけるPCI前後の脂質管理PCI前全体(n=71) 緊急PCI群(n=12) 待機的PCI群(n=59) LDL-C＜70を考慮する症例(n=58) LDL-C, mg/dL 86.6 ± 28.3 97.3 ± 25.0 84.4 ± 28.5 85.5 ± 26.7 スタチン内服, 人 (%) 57 (80.1) 6 (50.0) 51 (86.4) 47 (81.0) エゼチミブ内服, 人 (%) 9 (12.7) 2 (16.7) 7 (11.9) 8 (13.8) LDL-C＜70, 人 (%) 23 (32.4) 0 (0.0) 23 (39.0) 17 (29.3) 70≦LDL-C＜100, 人 (%) 28 (39.4) 7 (58.3) 21 (35.6) 25 (43.1) LDL-C≧100, 人 (%) 20 (28.2) 5 (41.7) 15 (25.4) 16 (27.6) PCI後全体(n=71) 緊急PCI群(n=12) 待機的PCI群(n=59) LDL-C＜70を考慮する症例(n=46) LDL-C, mg/dL 77.0 ± 20.8 78.9 ± 11.3 76.6 ± 22.2 76.3 ± 20.8 スタチン内服, 人 (%) 63 (88.7) 9 (75.0) 54 (91.5) 52 (88.5) エゼチミブ内服, 人 (%) 9 (12.7) 2 (16.7) 7 (11.9) 8 (13.8) LDL-C＜70, 人 (%) 24 (33.8) 2 (16.7) 22 (37.3) 19 (41.3) 70≦LDL-C＜100, 人 (%) 38 (53.5) 10 (83.3) 28 (47.5) 21 (45.7) LDL-C≧100, 人 (%) 9 (12.7) 0 (0.0) 9 (15.3) 6 (13.0) Engl J Med 2011;365:2078-2087.６）　 日本動脈硬化学会. 動脈硬化性疾患予防ガイドライン　2017年度版.７）　 Taguchi I, Iimuro S, Iwata H, Takashi-ma H, Abe M, Amiya E, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coro-nary Artery Disease （REAL-CAD）: A Randomized Superiority Trial. Circula-tion 2018;137:1997-2009.８）　 Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Ya-managa K, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percu-taneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Car-diol 2015;66:495-507.